STRAMUCIN^® is the newest topical antibiotic in the line of defense against bacterial infections resulting from those unfortunately all-too-frequent skin traumas such as cuts, scrapes, sutures, abrasions, etc.

STRAMUCIN^® is active against those micro-organisms, including methicillin-resistant staphylococci strains, responsible for the majority of skin infections.

STRAMUCIN^®, as a cream, is not greasy, sticky, or heavy on the skin, washes off easily with water, and is well suited to wet or oozing skin conditions.

Systemic absorption of mupirocin through intact skin is minimal, metabolic breakdown is rapid, and elimination is by the kidney.

STRAMUCIN^®: Demonstrated superior results in clinical trials vs. vehicle cream:

• In complete resolution or sustained improvement in signs and symptoms of infection
• In bacterial eradication rates of pathogenic organism at follow-up

Success rate* of STRAMUCIN^® vs. vehicle cream in clinical trials:^†

• In per-protocol population: 90.3% vs. 70.9%
• In modified intent-to-treat population: 90.6% vs. 70.5%
  

  (P-value < 0.001 for each)

STRAMUCIN^® inhibits bacterial protein synthesis and is bactericidal at concentrations achieved by topical administration.

Commonly susceptible species include:

• Staphylococcus aureus
• Staphylococcus epidermidis
• Coagulase-negative staphylococci
• Streptococcus species
• Haemophilus influenzae
• Neisseria gonorrhoeae
• Neisseria meningitidis
• Moraxella catarrhalis
• Pasteurella multocida

* Defined as complete resolution or sustained improvement of signs and symptoms of infection at 7 days post-treatment using the 4-point Skin Infection Rating Scale (SIRS).
^† Multi-centre, double-blind, randomized, parallel-group, vehicle-controlled study comparing safety and efficacy of STRAMUCIN^® (n=220) againstvehicle cream (n=219).

STRAMUCIN^® is easy to apply. Spread a small amount over affected areas 3 times daily, for up to 10 days. The treated area may be covered by a dressing.

STRAMUCIN^® is supplied in convenient 15-gram or 30-gram tubes.

• No dosage adjustment is necessary for children or the elderly, or for patients with hepatic or renal impairment.
• No evidence of cross-resistance between mupirocin and other antimicrobial drugs.

STRAMUCIN^® is approved for use in adults, including the elderly, and for children 18 months and older.

• Established safety and efficacy in pediatric populations (> 18 months).
• No overall difference in efficacy or safety in elderly (> 65 years) vs. younger patients.
• Exercise caution when administering to females during pregnancy, or during breast-feeding.

Side effects with STRAMUCIN^® are generally mild; a few people may experience unwanted effects, most commonly application site allergic reactions; these do not usually lead to discontinuation.

• In other clinical studies, reported adverse events included headache, rash, and nausea.
• Wipe off any cream and stop using STRAMUCIN^® in cases of adverse reaction, and inform doctor.

Mupirocin is identified by the WHO as an “Essential Anti-Infective” on its Model List of Essential Medicines.
WHO Model List

Contraindications:
STRAMUCIN^® is contraindicated in patients with known hypersensitivity to mupirocin or any of its excipients.
Serious warnings and precautions:
STRAMUCIN^® is not suitable for ophthalmic or intranasal use. Avoid contact with the eyes.

Other relevant warnings and precautions:

• Possible sensitization reaction or severe local irritation. Treatment should be discontinued, the product wiped off.
• Prolonged use may result in overgrowth of non-susceptible organisms.
• Possibility of pseudomembranous colitis. Discontinue treatment immediately.

Safety during pregnancy has not been established. Weigh potential benefits against possible hazards to the fetus. Exercise caution in nursing mothers.

For more information:
Consult the Product Monograph at https://www.canada.ca/en/health-canada.html for important information regarding adverse reactions, drug interactions and dosing information not discussed in this piece. The Product Monograph is also available by calling Glenmark Pharmaceuticals Canada Inc. at 1-844-801-7468.